Format

Send to

Choose Destination
Heart Fail Clin. 2018 Jan;14(1):27-39. doi: 10.1016/j.hfc.2017.08.004.

N-Terminal B-type Natriuretic Peptide in Heart Failure.

Author information

1
Cardiovascular Research Institute, National University of Singapore, National University Heart Centre, 1E Kent Ridge Road, NUHS Tower Block 9th Floor (Cardiology), Singapore 129788, Singapore; Christchurch Heart Institute, University of Otago, Riccarton Avenue, Christchurch 8014, New Zealand. Electronic address: mdcarthu@nus.edu.sg.

Abstract

Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a guideline-mandated biomarker in heart failure (HF). Used as an inclusion criterion for therapeutic trials, NT-proBNP enriches trial populations and is a valid surrogate endpoint. Its diagnostic performance is best validated in acute decompensated HF (ADHF). NT-proBNP offers prognostic information independent of standard clinical predictors and refines risk stratification. With the advent of combined angiotensin 2 type 1 receptor blockade and neprilysin inhibition (ARNI) NT-proBNP retains its relationship to cardiac status and is the marker of choice in assessment of possible ADHF and in serial monitoring of HF patients receiving ARNI treatment.

KEYWORDS:

Diagnosis; Heart failure; Monitoring; NT-proBNP; Prognosis

PMID:
29153198
DOI:
10.1016/j.hfc.2017.08.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center